Bellevue Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Bellevue Group’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-71,200	Closed	-$453K	–	229
2020 Q1	$453K	Sell	71,200 -1,700	-2%	-$13.6K	0.01%	165
2019 Q4	$760K	Buy	+72,900	New	+$530K	0.01%	154
2018 Q3	–	Sell	-17,250	Closed	-$784K	–	145
2018 Q2	$784K	Sell	17,250 -500	-3%	-$24.3K	0.07%	124
2018 Q1	$937K	Sell	17,750 -250	-1%	-$14.6K	0.09%	107
2017 Q4	$1.22M	Sell	18,000 -500	-3%	-$35K	0.13%	104
2017 Q3	$1.52M	Hold	18,500	–	–	0.16%	93
2017 Q2	$1.73M	Hold	18,500	–	–	0.2%	85
2017 Q1	$1.18M	Sell	18,500 -1,500	-8%	-$91.2K	0.16%	96
2016 Q4	$888K	Sell	20,000 -23,000	-53%	-$810K	0.18%	92
2016 Q3	$1.55M	Buy	+43,000	New	+$923K	0.28%	83
2016 Q2	–	Sell	-52,500	Closed	-$1.01M	–	134
2016 Q1	$1.01M	Buy	+52,500	New	+$1.11M	0.18%	96

Other funds holding CLVS

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Bellevue Group's CLVS Position: Q2 2020 in Review

Bellevue Group sold out of Clovis Oncology, Inc. (CLVS) in Q2 2020, closing a stake of 71,200 shares — an estimated $453K sold.

Bellevue Group first reported a position in CLVS in Q1 2016 and held it in 11 quarters. The position peaked at $1.73M in Q2 2017. 158 funds tracked by Wall St. Rank hold CLVS as of Q2 2020.

Bellevue Group reported no remaining Clovis Oncology, Inc. position as of Q2 2020 after selling out during the quarter.
Bellevue Group sold 71,200 Clovis Oncology, Inc. shares in Q2 2020, an estimated $453K.
Bellevue Group first reported a position in Clovis Oncology, Inc. in Q1 2016 and held it in 11 quarters.
Bellevue Group's Clovis Oncology, Inc. position peaked at $1.73M in Q2 2017.
158 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2020.

Based on Bellevue Group's 13F filing for Q2 2020, filed 13 Aug 2020.